

Q (c) determining the compound(s) which specifically affect(s) receptor expression. --


REMARKS

The Claims have been cancelled and rewritten in a form more commonly used for US filing. Multiple dependencies have been eliminated and dependent claims have been rewritten to incorporate all of the limitations of the independent claims from which they depend. Original Claim 22 has been cancelled and not rewritten.

An action on the merits is respectfully requested.

Respectfully submitted,
MARTIN ADAMCZEWSKI
CHRISTOPH METHFESSEL
THOMAS SCHULTE

By


Joseph C. Gil
Attorney for Applicants
Reg. No. 26,602

Bayer Corporation
100 Bayer Road
Pittsburgh, Pennsylvania 15205-9741
(412) 777-2342
FACSIMILE PHONE NUMBER:
(412) 777-5449
/vjt/JA0070